Category: Corporate NewsBy Rameda AdminAugust 7, 2024 Author: Rameda Admin Post navigationPreviousPrevious post:Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose IntoleranceNextNext post:Earning Release One Pager 2Q24Related PostsRameda Announces New Chairman and Additions to its Board of DirectorsJune 3, 2026Rameda Initiates First Acquisition of 2025July 7, 2025Record Dividend Distribution DisclosureJuly 7, 2025Rameda One-Pager 1Q25May 13, 2025Earnings Release One-Pager 4Q24March 10, 2025Earning Release One Pager 3Q24November 14, 2024
